|
Re: March Madness?
|
3
|
Resverlogix Corp.
|
Mar 12, 2018 12:16PM
|
|
TSX Review
|
2
|
Resverlogix Corp.
|
Mar 12, 2018 12:21PM
|
|
BIO-Europe Presentation
|
5
|
Zenith Epigenetics
|
Mar 13, 2018 12:09PM
|
|
Re: Novartis' canakinumab (Ilaris)
|
7
|
Resverlogix Corp.
|
Mar 13, 2018 03:20PM
|
|
Re: BIO-Europe Presentation
|
6
|
Zenith Epigenetics
|
Mar 13, 2018 04:05PM
|
|
BIO-Europe Presentation
|
2
|
Resverlogix Corp.
|
Mar 14, 2018 06:58AM
|
|
Re: BIO-Europe Presentation
|
3
|
Resverlogix Corp.
|
Mar 14, 2018 08:42AM
|
|
Re: Thought Provoking
|
4
|
Resverlogix Corp.
|
Mar 14, 2018 11:13AM
|
|
Apabetalone mentioned in kidney disease review
|
3
|
Resverlogix Corp.
|
Mar 14, 2018 11:20AM
|
|
BRD4 inhibition and PARP Inhibition
|
1
|
Zenith Epigenetics
|
Mar 14, 2018 11:22AM
|
|
Re: BIO-Europe Presentation
|
4
|
Resverlogix Corp.
|
Mar 14, 2018 01:41PM
|
|
MD&A and Financials up on SEDAR
|
5
|
Resverlogix Corp.
|
Mar 17, 2018 02:11PM
|
|
RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
|
Resverlogix Corp.
|
Mar 19, 2018 07:39AM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 07:42AM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
9
|
Resverlogix Corp.
|
Mar 19, 2018 11:11AM
|
|
Re: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL
|
6
|
Resverlogix Corp.
|
Mar 19, 2018 11:36AM
|
|
Denali/ATV and the advantages of BiOasis/xB3
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 19, 2018 11:55AM
|
|
Re: There is a positive side to the news...
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 12:08PM
|
|
Re: There is a positive side to the news...
|
3
|
Resverlogix Corp.
|
Mar 19, 2018 01:03PM
|
|
Re: Delivery peptide conjugates of Trastuzumab
|
1
|
BIOASIS TECHNOLOGIES INC
|
Mar 19, 2018 03:15PM
|
